Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients
The emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made it more difficult to prevent the virus from spreading despite available vaccines. Reports of breakthrough infections and decreased capacity of antibodies to neutralize variants raise the ques...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.869990/full |
| _version_ | 1818278571682037760 |
|---|---|
| author | Antti Hurme Antti Hurme Pinja Jalkanen Jemna Heroum Oona Liedes Saimi Vara Merit Melin Johanna Teräsjärvi Qiushui He Sakari Pöysti Sakari Pöysti Arno Hänninen Arno Hänninen Jarmo Oksi Tytti Vuorinen Tytti Vuorinen Anu Kantele Paula A. Tähtinen Lauri Ivaska Laura Kakkola Johanna Lempainen Johanna Lempainen Ilkka Julkunen Ilkka Julkunen |
| author_facet | Antti Hurme Antti Hurme Pinja Jalkanen Jemna Heroum Oona Liedes Saimi Vara Merit Melin Johanna Teräsjärvi Qiushui He Sakari Pöysti Sakari Pöysti Arno Hänninen Arno Hänninen Jarmo Oksi Tytti Vuorinen Tytti Vuorinen Anu Kantele Paula A. Tähtinen Lauri Ivaska Laura Kakkola Johanna Lempainen Johanna Lempainen Ilkka Julkunen Ilkka Julkunen |
| author_sort | Antti Hurme |
| collection | DOAJ |
| description | The emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made it more difficult to prevent the virus from spreading despite available vaccines. Reports of breakthrough infections and decreased capacity of antibodies to neutralize variants raise the question whether current vaccines can still protect against COVID-19 disease. We studied the dynamics and persistence of T cell responses using activation induced marker (AIM) assay and Th1 type cytokine production in peripheral blood mononuclear cells obtained from BNT162b2 COVID-19 mRNA vaccinated health care workers and COVID-19 patients. We demonstrate that equally high T cell responses following vaccination and infection persist at least for 6 months against Alpha, Beta, Gamma, and Delta variants despite the decline in antibody levels. |
| first_indexed | 2024-12-12T23:19:33Z |
| format | Article |
| id | doaj.art-e8a1c8a39f4545bf9a1055f78f72e7cf |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-12T23:19:33Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-e8a1c8a39f4545bf9a1055f78f72e7cf2022-12-22T00:08:19ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-04-011310.3389/fimmu.2022.869990869990Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent PatientsAntti Hurme0Antti Hurme1Pinja Jalkanen2Jemna Heroum3Oona Liedes4Saimi Vara5Merit Melin6Johanna Teräsjärvi7Qiushui He8Sakari Pöysti9Sakari Pöysti10Arno Hänninen11Arno Hänninen12Jarmo Oksi13Tytti Vuorinen14Tytti Vuorinen15Anu Kantele16Paula A. Tähtinen17Lauri Ivaska18Laura Kakkola19Johanna Lempainen20Johanna Lempainen21Ilkka Julkunen22Ilkka Julkunen23Institute of Biomedicine, University of Turku, Turku, FinlandDepartment of Infectious Diseases, Turku University Hospital and University of Turku, Turku, FinlandInstitute of Biomedicine, University of Turku, Turku, FinlandInstitute of Biomedicine, University of Turku, Turku, FinlandDepartment of Health Security, Finnish Institute for Health and Welfare, Helsinki, FinlandDepartment of Health Security, Finnish Institute for Health and Welfare, Helsinki, FinlandDepartment of Health Security, Finnish Institute for Health and Welfare, Helsinki, FinlandInstitute of Biomedicine, University of Turku, Turku, FinlandInstitute of Biomedicine, University of Turku, Turku, FinlandInstitute of Biomedicine, University of Turku, Turku, FinlandClinical Microbiology, Turku University Hospital, Turku, FinlandInstitute of Biomedicine, University of Turku, Turku, FinlandClinical Microbiology, Turku University Hospital, Turku, FinlandDepartment of Infectious Diseases, Turku University Hospital and University of Turku, Turku, FinlandInstitute of Biomedicine, University of Turku, Turku, FinlandClinical Microbiology, Turku University Hospital, Turku, FinlandMeilahti Vaccine Research Center, MeVac, Department of Infectious Diseases, Helsinki University Hospital and University of Helsinki, Helsinki, FinlandDepartment of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, FinlandDepartment of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, FinlandInstitute of Biomedicine, University of Turku, Turku, FinlandInstitute of Biomedicine, University of Turku, Turku, FinlandDepartment of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, FinlandInstitute of Biomedicine, University of Turku, Turku, FinlandClinical Microbiology, Turku University Hospital, Turku, FinlandThe emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made it more difficult to prevent the virus from spreading despite available vaccines. Reports of breakthrough infections and decreased capacity of antibodies to neutralize variants raise the question whether current vaccines can still protect against COVID-19 disease. We studied the dynamics and persistence of T cell responses using activation induced marker (AIM) assay and Th1 type cytokine production in peripheral blood mononuclear cells obtained from BNT162b2 COVID-19 mRNA vaccinated health care workers and COVID-19 patients. We demonstrate that equally high T cell responses following vaccination and infection persist at least for 6 months against Alpha, Beta, Gamma, and Delta variants despite the decline in antibody levels.https://www.frontiersin.org/articles/10.3389/fimmu.2022.869990/fullCovid-19BNT162b2vaccineT cell mediated immunityhumoral immunity |
| spellingShingle | Antti Hurme Antti Hurme Pinja Jalkanen Jemna Heroum Oona Liedes Saimi Vara Merit Melin Johanna Teräsjärvi Qiushui He Sakari Pöysti Sakari Pöysti Arno Hänninen Arno Hänninen Jarmo Oksi Tytti Vuorinen Tytti Vuorinen Anu Kantele Paula A. Tähtinen Lauri Ivaska Laura Kakkola Johanna Lempainen Johanna Lempainen Ilkka Julkunen Ilkka Julkunen Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients Frontiers in Immunology Covid-19 BNT162b2 vaccine T cell mediated immunity humoral immunity |
| title | Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients |
| title_full | Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients |
| title_fullStr | Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients |
| title_full_unstemmed | Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients |
| title_short | Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients |
| title_sort | long lasting t cell responses in bnt162b2 covid 19 mrna vaccinees and covid 19 convalescent patients |
| topic | Covid-19 BNT162b2 vaccine T cell mediated immunity humoral immunity |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.869990/full |
| work_keys_str_mv | AT anttihurme longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT anttihurme longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT pinjajalkanen longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT jemnaheroum longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT oonaliedes longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT saimivara longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT meritmelin longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT johannaterasjarvi longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT qiushuihe longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT sakaripoysti longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT sakaripoysti longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT arnohanninen longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT arnohanninen longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT jarmooksi longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT tyttivuorinen longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT tyttivuorinen longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT anukantele longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT paulaatahtinen longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT lauriivaska longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT laurakakkola longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT johannalempainen longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT johannalempainen longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT ilkkajulkunen longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients AT ilkkajulkunen longlastingtcellresponsesinbnt162b2covid19mrnavaccineesandcovid19convalescentpatients |